Highlights in management of early stage non-small cell lung cancer

In October 2013, Translational Lung Cancer Research is going to launch a special issue on management of Early Stage Non-Small Cell Lung Cancer (NSCLC). This special issue is guest-edited by Dr. Heather Wakelee, from Stanford Cancer Institute, Stanford University, USA. The scope of the special issue will be to provide cutting-edge literature on related fields and a platform for key experts to present their latest research results.

Apart from updates in surgical techniques, this special issue on Management of Early Stage NSCLC will present reviews on the importance of adequate lymph node sampling and on known prognostic biomarkers. We also have input on management for non-surgical patients, IR techniques, interventional pulmonology strategies and input from radiation oncologists. More interesting and exciting contents are coming up. Hope you will enjoy it.

Preview of the special issue:

• ❖ Interventional Pulmonology Approaches in diagnosis and treatment of early stage NSCLC

• Author: Arthur Sung

• Division of Pulmonary and Critical Care Medicine, New York Methodist Hospital, New York, USA

• ❖ Management of Ground Glass Opacities

• Author: Tetsuya Mitsudomi

• Aichi Cancer Center Hospital, Nagoya, Japan

• ❖ Potential Role of limited resections for small peripheral early stage NSCLC

• Author: Masahiro Tsuboi

• Department of Thoracic Surgery and Oncology, Tokyo Medical University and Hospital, Tokyo, Japan

• ❖ Towards Optimal Pathologic Staging of Resectable NSCLC

• Author: Raymond Osarogiagbon, Gail Darling

• Division of Oncology, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA

• ❖ Alternatives to Surgery in Early Stage Disease—SABR

• Author: Andrea Bezjak

• Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada

• ❖ Prognostic and Predictive Biomarkers in early stage NSCLC—tumor based approaches including gene signatures

• Author: Giorgio Scagliotti

• Department of Oncology, University of Turin, San Luigi Hospital, Regione Gonzale, Orbassano, Turin, Italy

• ❖ Prognostic and Predictive Biomarkers in early stage NSCLC—CTCs and serum/plasma markers

• Author: Fiona Blackhall

• Department of Medical Oncology, Christie Hospital, Manchester, UK

• ❖ Neoadjuvant chemotherapy in early-stage NSCLC

• Author: Enriqueta Felip-Font

• Oncology Service, Hospital Universitario de la Vall, Bacerlona

• ❖ Adjuvant Chemotherapy of Completely Resected Early Stage NSCLC

• Author: Heather Wakelee, Ying Liang

• Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA

• ❖ Adjuvant Molecularly Targeted Therapy—Epidermal Growth Factor Tyrosine Kinase Inhibition and Beyond

• Author: Lecia Sequist, Joel Neal

• Massachusetts General Hospital Cancer Center, Boston, USA

• ❖ Adjuvant Immune-Based Therapy

• Author: Charles Butts

• Cross Cancer Institute, 11560 University Avenue, Edmonton, AB, T6G 1Z2, Canada

• ❖ Post-Operative Radiation Therapy

• Author: Cécile Le Péchoux

• Institut Gustave Roussy, Radiotherapy Department, France

• ❖ Alternative to Surgery in Early Stage NSCLC—Interventional Radiologic Approaches

• Author: Bradley Pua

• New York-Presbyterian/Weill Cornell